Antitumor agent including irinotecan hydrochloride hydrate

• 收藏
• 分享

专利权人:

TAIHO PHARMACEUTICAL CO. LTD.

发明人:

Okabe Hiroyuki

申请号：

NZ71258414

公开号：

NZ712584A

申请日:

2014.03.27

申请国别(地区):

NZ

年份:

2018

代理人:

摘要：

Provided is a novel combination therapy using an FTD/TPI combination drug which exhibits remarkable antitumor effects, and few side effects. This antitumor agent is characterized in that one cycle of an administration schedule, in which, in a period of 14 days, the FTD/TPI combination drug is administered on days 1 to 5, and CPT-11 is administered on day 1, is repeated at least once.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/